Rarecells: Funding, Investors & Team (Sep 2026)
Rarecells, Inc. is a healthcare company focused on the development and commercialization of non-invasive Early Cancer Detection tests. These tests are based on the ISET® platform technology that is able to extract from blood cancer cells from any type of cancer. Cancer cells extracted by ISET® are then diagnostically identified through immune-morpho molecular analyses combined with image analyses and AI. This approach is believed to be a significant advancement in the highly sensitive non-invasive detection of cancer’s signals providing a powerful tool for early cancer detection through the identification of the first circulating cancer cells.
Rarecells has raised $5.0M across 1 funding round on record, the most recent a Series A of $5.0M announced in Dec 2021.
That round is below the $8.0M median round size for Biotechnology companies tracked on FundedIQ over the last two years.
Rarecells Company Profile and Key Stats
Latest funding round on record: Dec 2021.
Rarecells Funding Rounds
Rarecells Founders and Leadership Team
No contact details are on record for this team yet.
Rarecells Funding Compared to Other Biotechnology Startups
Rarecells' latest round of $5.0M is below the median round in Biotechnology. Medians cover the last 24 months of disclosed rounds.
Funded Startups Like Rarecells in Biotechnology and Paris
Companies Similar to Rarecells
Brenus Pharma is a platform that uses allogeneic techniques to create immune therapy with the goal of…
TISSIUM is a privately owned medical device company based in Paris, France that is dedicated to the rapid…
NicOx is a biopharmaceutical company that focuses on creating and selling nitric oxide-donating drugs for…
Advicenne is a specialty pharmaceutical company dedicated to improving the lives of patients who suffer from…
One Biosciences was founded in Paris, Ile-de-France, France by Magali Richard, David Schilansky, and Céline…
Inventiva Pharma is a biopharmaceutical company in the clinical stage that focuses on creating oral small…
NETRIS Pharma develops therapeutic molecules for treating cancer by targeting dependence receptors for the…
AbIONYX Pharma is a biotechnology company that is focused on providing innovative therapies for indications…
Founded in 2003, Nanobiotix is at the forefront of nanomedicine and is committed to revolutionizing patient…
Theraclion specializes in high-tech medical equipment using high-intensity focused ultrasound (HIFU). They…
Abivax, a clinical stage biotechnology company, is mobilizing the body’s natural immune machinery to treat…
AB Science was established in 2001 by a group of individuals in the medical and business fields who are…
Rarecells Funding FAQs
What does Rarecells do?
Rarecells, Inc. is a healthcare company focused on the development and commercialization of non-invasive Early Cancer Detection tests. These tests are based on the ISET® platform technology that is able to extract from blood cancer cells from any type of cancer. Cancer cells extracted by ISET® are then diagnostically identified through immune-morpho molecular analyses combined with image analyses and AI. This approach is believed to be a significant advancement in the highly sensitive non-invasive detection of cancer’s signals providing a powerful tool for early cancer detection through the identification of the first circulating cancer cells.
How much funding has Rarecells raised?
Rarecells has raised $5.0M across 1 round on record. The most recent is a Series A of $5.0M announced in Dec 2021.
When did Rarecells last raise funding?
Rarecells' most recent funding round on record is a Series A of $5.0M, announced in Dec 2021.
Who is the CEO of Rarecells?
Davide Brechot is listed as CEO at Rarecells.
Where is Rarecells headquartered?
Rarecells is based in Paris, Ile-De-France, France.
How many employees does Rarecells have?
Rarecells is in the 11-50 employee band.
How does Rarecells' funding compare to other Biotechnology startups?
Rarecells' latest round of $5.0M is below the $8.0M median round size for Biotechnology companies on FundedIQ across 4,182 tracked companies over the last two years.
About FundedIQ's Rarecells Funding Data
FundedIQ tracks announced funding rounds and refreshes this profile every week. Round dates, stages and amounts are normalised to a single format, converted to US dollars, and de-duplicated: two records of the same round announced days apart are merged, and two genuinely different rounds are kept apart on the amounts they disclose. Amounts shown are the disclosed figures only — a round announced without a number is listed and excluded from the total rather than estimated.
Employee counts are reported bands, not exact headcounts. Founder and executive names carry the job title on record. Anything we do not hold for Rarecells is left off this page rather than filled in.
Know who just raised. Then know who to reach.
Every newly funded startup with its round, its investors and its founders: delivered weekly by email, or searchable in the app.
Alerts from $19/mo · Pro from $99/mo. Card required, nothing charged until day 15, and we email you 3 days before that.